These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 31010844)

  • 41. Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia.
    Frismantas V; Dobay MP; Rinaldi A; Tchinda J; Dunn SH; Kunz J; Richter-Pechanska P; Marovca B; Pail O; Jenni S; Diaz-Flores E; Chang BH; Brown TJ; Collins RH; Uhrig S; Balasubramanian GP; Bandapalli OR; Higi S; Eugster S; Voegeli P; Delorenzi M; Cario G; Loh ML; Schrappe M; Stanulla M; Kulozik AE; Muckenthaler MU; Saha V; Irving JA; Meisel R; Radimerski T; Von Stackelberg A; Eckert C; Tyner JW; Horvath P; Bornhauser BC; Bourquin JP
    Blood; 2017 Mar; 129(11):e26-e37. PubMed ID: 28122742
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative study of a novel nucleoside analogue (Troxatyl, troxacitabine, BCH-4556) and AraC against leukemic human tumor xenografts expressing high or low cytidine deaminase activity.
    Gourdeau H; Bibeau L; Ouellet F; Custeau D; Bernier L; Bowlin T
    Cancer Chemother Pharmacol; 2001 Mar; 47(3):236-40. PubMed ID: 11320667
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Zebularine induces chemosensitization to methotrexate and efficiently decreases AhR gene methylation in childhood acute lymphoblastic leukemia cells.
    Andrade AF; Borges KS; Castro-Gamero AM; Silveira VS; Suazo VK; Oliveira JC; Moreno DA; de Paula Queiroz RG; Scrideli CA; Tone LG
    Anticancer Drugs; 2014 Jan; 25(1):72-81. PubMed ID: 24052107
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Interactions between acute lymphoblastic leukemia and bone marrow stromal cells influence response to therapy.
    Tesfai Y; Ford J; Carter KW; Firth MJ; O'Leary RA; Gottardo NG; Cole C; Kees UR
    Leuk Res; 2012 Mar; 36(3):299-306. PubMed ID: 21889797
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bryostatin 1-induced modulation of the acute lymphoblastic leukemia cell line Reh.
    al-Katib A; Mohammad RM; Khan K; Dan ME; Pettit GR; Sensenbrenner LL
    J Immunother Emphasis Tumor Immunol; 1993 Jul; 14(1):33-42. PubMed ID: 8399068
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inhibition of Mnk enhances apoptotic activity of cytarabine in acute myeloid leukemia cells.
    Li P; Diab S; Yu M; Adams J; Islam S; Basnet SK; Albrecht H; Milne R; Wang S
    Oncotarget; 2016 Aug; 7(35):56811-56825. PubMed ID: 27462781
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacology of intracellular cytosine-arabinoside-5'-triphosphate in malignant cells of pediatric patients with initial or relapsed leukemia and in normal lymphocytes.
    Koehl U; Hollatz G; Rohrbach E; Visschedyk K; Cinatl J; Kornhuber B; Kreuter J; Mutschler E; Schwabe D
    Cancer Chemother Pharmacol; 2007 Sep; 60(4):467-77. PubMed ID: 17171362
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The synergism of 6-mercaptopurine plus cytosine arabinoside followed by PEG-asparaginase in human leukemia cell lines (CCRF/CEM/0 and (CCRF/CEM/ara-C/7A) is due to increased cellular apoptosis.
    Nandy P; Periclou AP; Avramis VI
    Anticancer Res; 1998; 18(2A):727-37. PubMed ID: 9615712
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sgc8 aptamer targeted glutathione-responsive nanoassemblies containing Ara-C prodrug for the treatment of acute lymphoblastic leukemia.
    Fang Z; Wang X; Sun Y; Fan R; Liu Z; Guo R; Xie D
    Nanoscale; 2019 Dec; 11(47):23000-23012. PubMed ID: 31769777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
    Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
    Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bafilomycin A1 targets both autophagy and apoptosis pathways in pediatric B-cell acute lymphoblastic leukemia.
    Yuan N; Song L; Zhang S; Lin W; Cao Y; Xu F; Fang Y; Wang Z; Zhang H; Li X; Wang Z; Cai J; Wang J; Zhang Y; Mao X; Zhao W; Hu S; Chen S; Wang J
    Haematologica; 2015 Mar; 100(3):345-56. PubMed ID: 25512644
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia--implications for treatment of infants.
    Pieters R; den Boer ML; Durian M; Janka G; Schmiegelow K; Kaspers GJ; van Wering ER; Veerman AJ
    Leukemia; 1998 Sep; 12(9):1344-8. PubMed ID: 9737681
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
    Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
    J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Mice transduced with double-mutant dihydrofolate reductase-cytidine deaminase fusion gene attained protection from high dose chemotherapy].
    Lu P; Lu Y; Pang K; Wang SB; Chen JQ; Xu HM; Wang JK; Zhao SC
    Zhonghua Wai Ke Za Zhi; 2005 Aug; 43(15):998-1001. PubMed ID: 16194358
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sugar-modified poly(propylene imine) dendrimers as drug delivery agents for cytarabine to overcome drug resistance.
    Szulc A; Pulaski L; Appelhans D; Voit B; Klajnert-Maculewicz B
    Int J Pharm; 2016 Nov; 513(1-2):572-583. PubMed ID: 27667754
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fludarabine-mediated circumvention of cytarabine resistance is associated with fludarabine triphosphate accumulation in cytarabine-resistant leukemic cells.
    Yamamoto S; Yamauchi T; Kawai Y; Takemura H; Kishi S; Yoshida A; Urasaki Y; Iwasaki H; Ueda T
    Int J Hematol; 2007 Feb; 85(2):108-15. PubMed ID: 17321987
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Modulation of cIAP-1 by novel antitubulin agents when combined with bryostatin 1 results in increased apoptosis in the human early pre-B acute lymphoblastic leukemia cell line Reh.
    Wall NR; Mohammad RM; Nabha SM; Pettit GR; Al-Katib AM
    Biochem Biophys Res Commun; 1999 Dec; 266(1):76-80. PubMed ID: 10581168
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bcl-2, bax and bcl-xL expression in human sensitive and resistant leukemia cell lines.
    Nuessler V; Stötzer O; Gullis E; Pelka-Fleischer R; Pogrebniak A; Gieseler F; Wilmanns W
    Leukemia; 1999 Nov; 13(11):1864-72. PubMed ID: 10557064
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
    Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
    Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Antiproliferative activity and mechanism of action of fatty acid derivatives of arabinofuranosylcytosine in leukemia and solid tumor cell lines.
    Bergman AM; Kuiper CM; Voorn DA; Comijn EM; Myhren F; Sandvold ML; Hendriks HR; Peters GJ
    Biochem Pharmacol; 2004 Feb; 67(3):503-11. PubMed ID: 15037202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.